| PXS US FDA Convenes Advisory Committee for Bronchitol |
| 26/03/19 | | | Share |
|
| PXS Becoming a substantial holder |
| 05/03/19 | | | Share |
|
| PXS Ceasing to be a substantial holder |
| 04/03/19 | | | Share |
|
| PXS Boehringer Completes Enrollment of Phase 2A Trial in NASH |
| 25/02/19 | | | Share |
|
| PXS Pharmaxis Commences Phase 1 LOX Clinical Trial |
| 22/02/19 | PRICE SENSITIVE | | Share |
|
| PXS Half Yearly Report and Accounts |
| 14/02/19 | PRICE SENSITIVE | | Share |
|
| PXS Quarterly Shareholder Update - December 2018 |
| 30/01/19 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly |
| 30/01/19 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Announces LOXL2 Program Phase 2 Ready |
| 17/01/19 | PRICE SENSITIVE | | Share |
|
| PXS PHARMAXIS ANNOUNCES RESUBMISSION OF BRONCHITOL NDA IN USA |
| 20/12/18 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Announces First Relaunch Sales of Aridol in USA |
| 13/12/18 | PRICE SENSITIVE | | Share |
|
| PXS Change in substantial holding |
| 27/11/18 | | | Share |
|
| PXS Appendix 3B - exercise of employee options |
| 26/11/18 | | | Share |
|
| PXS Final Director's Interest Notice |
| 22/11/18 | | | Share |
|
| PXS Change of Director's Interest Notice |
| 22/11/18 | | | Share |
|
| PXS Appendix 3B - Grant of options to CEO |
| 22/11/18 | | | Share |
|
| PXS Results of Meeting |
| 22/11/18 | | | Share |
|
| PXS Pharmaxis AGM - CEO Presentation |
| 22/11/18 | PRICE SENSITIVE | | Share |
|
| PXS Chairman's Address to Shareholders |
| 22/11/18 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis AGM - Withdrawal of Resolution |
| 22/11/18 | | | Share |
|
| PXS Investor Research Briefing Presentations |
| 20/11/18 | | | Share |
|
| PXS LOX Inhibitor Program for Pancreatic Cancer Phase 1 Ready |
| 20/11/18 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Releases Positive Results of Phase 1 Clinical Tria |
| 15/11/18 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Investor Research Briefing |
| 15/11/18 | | | Share |
|
| PXS Quarterly Shareholder Update - September 2018 |
| 26/10/18 | | | Share |
|
| PXS Appendix 4C - quarterly |
| 26/10/18 | PRICE SENSITIVE | | Share |
|
| PXS Copy of Corporate Governance Statement |
| 19/10/18 | | | Share |
|
| PXS Appendix 4G |
| 19/10/18 | | | Share |
|
| PXS Annual Report to shareholders |
| 19/10/18 | | | Share |
|
| PXS Notice of Annual General Meeting/Proxy Form |
| 19/10/18 | | | Share |
|
| PXS Updated Investor Presentation |
| 11/10/18 | | | Share |
|
| PXS Positive Phase 1 Results of Phase 1 Study - LOXL2 Inhibitor |
| 11/10/18 | PRICE SENSITIVE | | Share |
|
| PXS Director Retirement |
| 04/10/18 | | | Share |
|
| PXS Change in substantial holding |
| 26/09/18 | | | Share |
|
| PXS Appendix 3B - exercise of employee options |
| 26/09/18 | | | Share |
|
| PXS Change in substantial holding |
| 25/09/18 | | | Share |
|
| PXS Change in substantial holding from AEF |
| 25/09/18 | | | Share |
|
| PXS Appendix 3B - exercise of 25,000 employee options |
| 21/09/18 | | | Share |
|
| PXS Change of Director's Interest Notice - Metters |
| 21/09/18 | | | Share |
|
| PXS Change of Director's Interest Notice - W Delaat |
| 21/09/18 | | | Share |
|
| PXS Change of Director's Interest Notice - Phillips |
| 21/09/18 | | | Share |
|
| PXS Change of Director's Interest Notice - McComas |
| 21/09/18 | | | Share |
|
| PXS Change of Director's Interest Notice - S Buckingham |
| 21/09/18 | | | Share |
|
| PXS Section 708A Notice |
| 21/09/18 | | | Share |
|
| PXS Appendix 3B - Placement Tranche 2 |
| 21/09/18 | | | Share |
|
| PXS Initial Director's Interest Notice - E Rayner |
| 18/09/18 | | | Share |
|
| PXS Director Appointment - Edward Rayner |
| 18/09/18 | | | Share |
|
| PXS Results of Meeting |
| 17/09/18 | | | Share |
|
| PXS Chairman's Introductory Comments to Shareholders |
| 17/09/18 | | | Share |
|
| PXS Investor Presentation |
| 28/08/18 | | | Share |
|
| PXS Notice of Extraordinary General Meeting/Proxy Form |
| 20/08/18 | | | Share |
|
| PXS Notice of initial substantial holder |
| 17/08/18 | | | Share |
|
| PXS Preliminary Final Report |
| 17/08/18 | PRICE SENSITIVE | | Share |
|
| PXS Change in substantial holding |
| 16/08/18 | | | Share |
|
| PXS FDA Factory Approval and Relaunch of Aridol in US Market |
| 15/08/18 | PRICE SENSITIVE | | Share |
|
| PXS Section 708A Notice |
| 14/08/18 | | | Share |
|
| PXS Appendix 3B - Placement Tranche 1 |
| 14/08/18 | | | Share |
|
| PXS Capital Raising Presentation |
| 06/08/18 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Announces A$24m Placement |
| 06/08/18 | PRICE SENSITIVE | | Share |
|
| PXS Trading Halt Announcement - System Upgrade |
| 06/08/18 | PRICE SENSITIVE | | Share |
|
| PXS Trading Halt |
| 03/08/18 | PRICE SENSITIVE | | Share |
|
| PXS Quarterly Shareholder Update - June 2018 |
| 27/07/18 | PRICE SENSITIVE | 441.24KB | Share |
|
| PXS Appendix 4C - quarterly |
| 27/07/18 | PRICE SENSITIVE | 122.6KB | Share |
|
| PXS Proposed Issue of Securities to Chief Executive Officer |
| 25/07/18 | | 111.76KB | Share |
|
| PXS Appendix 3B - Grant of Employee Options and Shares |
| 25/07/18 | | 130.93KB | Share |
|
| PXS Appendix 3B - Exercise of Employee Options |
| 25/07/18 | | 129.31KB | Share |
|
| PXS Appendix 3B - Exercise of Employee Options |
| 17/07/18 | | 129.32KB | Share |
|
| PXS Change of Director's Interest Notice - Expiring Options |
| 02/07/18 | | 71.02KB | Share |
|
| PXS LOXL2 Program Attracts Strong Partner Interest at BIO18 |
| 14/06/18 | PRICE SENSITIVE | 120.63KB | Share |
|
| PXS Quarterly Shareholder Update - March 2018 |
| 30/04/18 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly |
| 30/04/18 | PRICE SENSITIVE | | Share |
|
| PXS Change in substantial holding |
| 05/04/18 | | | Share |
|
| PXS Change in substantial holding from AEF |
| 04/04/18 | | | Share |
|
| PXS Appendix 3B - Exercise of Employee Options |
| 08/03/18 | | | Share |
|
| PXS Half Yearly Report and Accounts |
| 15/02/18 | PRICE SENSITIVE | | Share |
|
| PXS Investor Presentation - 7 February 2018 |
| 07/02/18 | | | Share |
|
| PXS Investor Presentation - 30 January 2018 |
| 31/01/18 | | | Share |
|
| PXS Appendix 4C - quarterly |
| 29/01/18 | PRICE SENSITIVE | | Share |
|
| PXS Quarterly Shareholder Update - December 2017 |
| 29/01/18 | | | Share |
|
| PXS Pharmaxis Earns A$15 Million Milestone Payment |
| 11/01/18 | PRICE SENSITIVE | | Share |
|
| PXS New Australian PBS Listing for Brocnhitol |
| 02/01/18 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Acquires Control, Increases Stake in LOXL2 Program |
| 14/12/17 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 3B - Grant of Employee Peformance Rights |
| 14/11/17 | | | Share |
|
| PXS Change of Director's Interest Notice - G Phillips |
| 14/11/17 | | | Share |
|
| PXS Results of Meeting |
| 14/11/17 | | | Share |
|
| PXS CEO Presentation to 2017 AGM |
| 13/11/17 | | | Share |
|
| PXS Chairman's Address to Shareholders |
| 13/11/17 | | | Share |
|
| PXS Quarterly Shareholder Update - September 2017 |
| 27/10/17 | | | Share |
|
| PXS Appendix 4C - quarterly |
| 27/10/17 | PRICE SENSITIVE | | Share |
|
| PXS Investor Presentation - 23 October 2017 |
| 23/10/17 | | | Share |
|
| PXS Pharmaxis Strengthens Drug Discovery Capability |
| 19/10/17 | | | Share |
|
| PXS Copy of Corporate Governance Statement - 12 October 2017 |
| 12/10/17 | | | Share |
|
| PXS 2017 Appendix 4G - Key to Disclosures |
| 12/10/17 | | | Share |
|
| PXS Notice of 2017 Annual General Meeting/Proxy Form |
| 12/10/17 | | | Share |
|
| PXS 2017 Annual Report to Shareholders |
| 12/10/17 | | | Share |
|
| PXS Appendix 3B - Exercise of employee options |
| 09/10/17 | | | Share |
|
| PXS Investor Presentation |
| 08/09/17 | | | Share |
|
| PXS Interview with CEO - New Phase 2 Study by Boehringer |
| 08/09/17 | | | Share |
|
| PXS Boehringer Initiating Phase 2a Study Diabetic Retinopathy |
| 08/09/17 | PRICE SENSITIVE | | Share |
|
| PXS Antifibrotic LOXL2 Program Clears Preclinical Development |
| 06/09/17 | PRICE SENSITIVE | | Share |
|
